Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Earnings Call Transcript
Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.86, expectations were $-1.14. Vir Biotechnology, Inc.
Vir Biotechnology Inc. (VIR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 3,037,948 | $30,561,757 | +3537% | 0% |
| 2. | D E Shaw D. E. Shaw | 769,144 | $7,737,589 | -13% | 0% |
| 3. | Millennium Management Israel Englander | 410,057 | $4,125,173 | -36% | 0% |
| 4. | TwinBeech Capital Jinghua Yan | 319,872 | $3,217,912 | +223% | 0.05% |
| 5. | Hudson Bay Capital Management Sander Gerber | 290,000 | $2,917,400 | +40% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.73 | 2,500 | Director | 10,000 | 2023-03-01 | Filing | |
| $24.96 | 2,500 | Director | 7,500 | 2023-01-05 | Filing | |
| $25.25 | 2,500 | Director | 5,000 | 2023-01-04 | Filing | |
| $25.60 | 2,500 | Director | 2,500 | 2023-01-03 | Filing | |
| $43.39 | 12 | Officer | 12 | 2021-11-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.46 | 72,995 | Officer, Director | 678,457 | 2024-04-03 | Filing | |
| $10.05 | 2,711 | Officer | 132,069 | 2024-04-01 | Filing | |
| $9.89 | 6,008 | Officer | 100,492 | 2024-03-27 | Filing | |
| $10.05 | 12,296 | Officer | 134,780 | 2024-02-22 | Filing | |
| $10.05 | 14,568 | Officer | 250,111 | 2024-02-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,864,579 | $169,657,665 | 0% | |
| 2. | 16,684,041 | $167,841,452 | 1.49% | |
| 3. | 12,297,139 | $123,709,219 | 0% | |
| 4. | 6,912,082 | $69,535,545 | 0% | |
| 5. | 3,965,549 | $39,893,423 | 0.03% |
News See All
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Earnings Call Transcript
Operator: Hello, and welcome to Vir Biotechnology's Third Quarter 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
10 Oversold Healthcare Stocks to Buy
In this article, we will take a look at the 10 healthcare stocks to buy.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2023 Earnings Call Transcript
Operator: Hello. Welcome to Vir Biotechnology Second Quarter 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
5 Oversold NASDAQ Stocks to Buy
San Francisco, California-based Vir Biotechnology, Inc. (NASDAQ:VIR) is a commercial-stage immunology company focused on the development of therapies to treat and prevent serious infectious diseases.
5 Stocks with Biggest Upside Potential According to Analysts
In this article, we will take a look at the 5 stocks with biggest upside potential according to analysts.
5 Best Revenue Growth Stocks to Buy
In this piece, we will take a look at the five best revenue growth stocks to buy.
5 Most Promising Biotech Stocks According to Analysts
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) was founded in 2008 and is headquartered in Boston, Massachusetts.
5 High Growth Pharma Stocks that are Profitable
Halozyme Therapeutics, Inc. (NASDAQ:HALO)'s third quarter of 2022 results saw the firm bring in $209 million in revenue, which marked a strong 80% annual growth.